Bremelanotide, approved by the FDA in 2019 under the brand name Vyleesi, is used to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts as a melanocortin receptor agonist, primarily targeting MC1 and MC4 receptors in the hypothalamus, an area involved in sexual behavior. Activation of these receptors increases dopamine release, enhancing sexual desire. Though the precise mechanism is unclear, it helps restore balance between excitatory and inhibitory sexual signals. It is taken at least 45 minutes before sexual activity.
Hall, K. S. K., & Binik, Y. M. (2020). Principles and practice of sex therapy (6th ed.). The Guilford Press.
Paauw, D. (2024). Newer outpatient therapies and treatments, an issue of Medical Clinics of North America. Elsevier.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about PT-141 by Hubio Pharm, consult with your doctor or healthcare professional.
Paauw, D. (2024). Newer outpatient therapies and treatments, an issue of Medical Clinics of North America. Elsevier.
Paauw, D. (2024). Newer outpatient therapies and treatments, an issue of Medical Clinics of North America. Elsevier.
Hall, K. S. K., & Binik, Y. M. (2020). Principles and practice of sex therapy (6th ed.). The Guilford Press.
Paauw, D. (2024). Newer outpatient therapies and treatments, an issue of Medical Clinics of North America. Elsevier.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Home
